These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 31963413)

  • 21. The immunobiology of cancer immunosurveillance and immunoediting.
    Dunn GP; Old LJ; Schreiber RD
    Immunity; 2004 Aug; 21(2):137-48. PubMed ID: 15308095
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent advances and challenges of immune checkpoint inhibitors in immunotherapy of non-small cell lung cancer.
    Wu Z; Man S; Sun R; Li Z; Wu Y; Zuo D
    Int Immunopharmacol; 2020 Aug; 85():106613. PubMed ID: 32450531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 24. Immunotherapy in Advanced Non-Small Cell Lung Cancer.
    Huang J; Reckamp KL
    Semin Respir Crit Care Med; 2020 Jun; 41(3):400-408. PubMed ID: 32450594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1.
    Villanueva N; Bazhenova L
    Ther Adv Respir Dis; 2018; 12():1753466618794133. PubMed ID: 30215300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly.
    Sgambato A; Casaluce F; Gridelli C
    Expert Opin Biol Ther; 2017 May; 17(5):565-571. PubMed ID: 28276698
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions.
    Soo RA; Lim SM; Syn NL; Teng R; Soong R; Mok TSK; Cho BC
    Lung Cancer; 2018 Jan; 115():12-20. PubMed ID: 29290252
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunotherapy in non-small-cell lung cancer: from targeted molecules to resistance patterns.
    Brassart-Pasco S; Dalstein V; Brassart B; Dewolf M; Clavel C; Oudart JB
    Pharmacogenomics; 2020 Jul; 21(10):705-720. PubMed ID: 32567537
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic escape of immunosurveillance by malignant cell precursors.
    Galassi C; Galluzzi L
    EMBO J; 2023 May; 42(10):e114050. PubMed ID: 37051718
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combining immunotherapies to treat non-small cell lung cancer.
    Spagnuolo A; Gridelli C
    Expert Rev Respir Med; 2019 Jul; 13(7):621-634. PubMed ID: 31116072
    [No Abstract]   [Full Text] [Related]  

  • 31. Patrolling monocytes control tumor metastasis to the lung.
    Hanna RN; Cekic C; Sag D; Tacke R; Thomas GD; Nowyhed H; Herrley E; Rasquinha N; McArdle S; Wu R; Peluso E; Metzger D; Ichinose H; Shaked I; Chodaczek G; Biswas SK; Hedrick CC
    Science; 2015 Nov; 350(6263):985-90. PubMed ID: 26494174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer.
    Jiang J; Jin Z; Zhang Y; Peng L; Zhang Y; Zhu Z; Wang Y; Tong D; Yang Y; Wang J; Yang Y; Xiao K
    Front Immunol; 2021; 12():646874. PubMed ID: 33927719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunotherapy Comes of Age in Lung Cancer.
    Khanna P; Blais N; Gaudreau PO; Corrales-Rodriguez L
    Clin Lung Cancer; 2017 Jan; 18(1):13-22. PubMed ID: 27461776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Advances in the Treatment of Non-Small Cell Lung Cancer: Immunotherapy.
    Patel SA; Weiss J
    Clin Chest Med; 2020 Jun; 41(2):237-247. PubMed ID: 32402359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New Immunotherapy and Lung Cancer.
    Sánchez de Cos Escuín J
    Arch Bronconeumol; 2017 Dec; 53(12):682-687. PubMed ID: 28823733
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in immune checkpoint therapy in non-small cell lung cancer and opportunities for nanoparticle-based therapy.
    Sanaei MJ; Pourbagheri-Sigaroodi A; Kaveh V; Abolghasemi H; Ghaffari SH; Momeny M; Bashash D
    Eur J Pharmacol; 2021 Oct; 909():174404. PubMed ID: 34363829
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer immunosurveillance and immunoediting: the roles of immunity in suppressing tumor development and shaping tumor immunogenicity.
    Smyth MJ; Dunn GP; Schreiber RD
    Adv Immunol; 2006; 90():1-50. PubMed ID: 16730260
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
    Garon EB
    Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current uses of check inhibitors in the fight against advanced and/or metastatic lung cancer: will immunotherapy overcome chemotherapy?
    Cetin B; Bilgetekin İ; Ozet A
    Curr Probl Cancer; 2019 Feb; 43(1):43-53. PubMed ID: 30104030
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer immunosurveillance and immunoediting by natural killer cells.
    Gross E; Sunwoo JB; Bui JD
    Cancer J; 2013; 19(6):483-9. PubMed ID: 24270347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.